Sailong Pharmaceutical Group Co., Ltd. engages in the research, development, production, and marketing of pharmaceutical intermediates, raw materials, and preparations. It also offers related technical services. Its key products include thymofaxine for injection, argatroban injection and raw materials, tigecycline for injection and raw materials, monosialotetrahexose ganglioside sodium injection and raw materials, cerebroprotein hydrolysate for injection, milrinone injection, parecoxib sodium for injection and raw materials, tranexamic acid injection, clindamycin phosphate for injection, and pantoprazole sodium for injection. The company was founded by Nan Gui Cai on April 3, 2002 and is headquartered in Zhuhai, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company